Treatment outcomes in a 10-year geographic cohort of patients with Adult-onset Still ’ s Disease : Case series and literature review

Introduction: Adult-onset Stills Disease (AOSD) is a rare immuno-inflammatory disease with an unpredictable course. Contemporary treatment with biological agents is commonplace but the efficacy of treatment and effects on long-term outcomes are poorly defined. We investigated prognostic markers and evaluated outcomes in an Australian cohort of hospitalized patients with AOSD diagnosed and treated over 10 years. Methods: Patients greater than 18 years of age with a discharge ICD-10 code for AOSD were selected from medical records at 3 tertiary hospitals in Perth, Western Australia from 2009-2019. Demographic data, and clinical and serological outcomes after 12 months of follow-up were collected. Relationships between plasma ferritin and clinical remission, flare rate, need for conventional treatment with or without conventional or biological disease-modifying agents (csDMARD and bDMARD) and Physician Global Assessment score (PGA) were evaluated, as were the effect of treatments on serologic markers of remission and PGA. Fishers exact tests for a categorical comparisons and Mann-Whitney U-tests for comparison of continuous outcomes were performed. P < 0.05 was considered statistically significant. Results: All patients received corticosteroid therapy and 18 of 24 also received csDMARDs. Of these, 8 progressed to bDMARDs. Lower baseline ferritin concentrations were observed in those who achieved complete remission, required csDMARDs +/bDMARDs, or had more flares per 100 patient-years and lower PGA scores, but the results were not statistically significant. Serological markers of remission decreased markedly with all treatments, but no significant differences between treatments or in patients achieving remission was observed. Conclusions: Long term follow-up was limited but remission rates appeared low. No unequivocal predictors of treatment response or outcome were identified. A trend towards greater use of csDMARDs and bDMARDs, and low PGA scores (poor outcome at 12 months), implying worse outcomes was observed with hyperferritinemia. Accordingly, marked hyperferritinemia may be a biomarker for more sustained or severe AOSD manifestations and predispose to more relapses. Further research is required to examine this possibility in more detail. Tasman Medical Journal 2021; 3(2): 94-10

[1]  Jian Xu,et al.  Clinical features and current treatments of adult-onset Still's disease: a multicentre survey of 517 patients in China. , 2019, Clinical and experimental rheumatology.

[2]  P. Galozzi,et al.  Adult-Onset Still’s Disease: Molecular Pathophysiology and Therapeutic Advances , 2018, Drugs.

[3]  J. Pouchot,et al.  Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review , 2018, Critical Care.

[4]  J. Pouchot,et al.  Validation of the Fautrel classification criteria for adult-onset Still's disease. , 2018, Seminars in arthritis and rheumatism.

[5]  H. Fang,et al.  Biological therapy of traditional therapy-resistant adult-onset Still’s disease: an evidence-based review , 2018, Therapeutics and clinical risk management.

[6]  E. Feist,et al.  Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). , 2017, Seminars in arthritis and rheumatism.

[7]  F. Spertini,et al.  Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease , 2017, Annals of the rheumatic diseases.

[8]  T. Henry,et al.  Treatment of adult-onset Still’s disease: a review , 2014, Therapeutics and clinical risk management.

[9]  F. Martinon,et al.  Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart , 2014, Immunologic Research.

[10]  S. Castañeda,et al.  Efficacy of Tocilizumab in Conventional Treatment–Refractory Adult‐Onset Still's Disease: Multicenter Retrospective Open‐Label Study of Thirty‐Four Patients , 2014, Arthritis & rheumatology.

[11]  H. Amital,et al.  Diagnosis and classification of adult Still's disease. , 2014, Journal of autoimmunity.

[12]  A. Kontzias,et al.  Erratum to: Adult-onset Still’s disease: pathogenesis, clinical manifestations and therapeutic advances , 2012, Drugs.

[13]  M. Koutsilieris,et al.  Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies , 2012, International journal of inflammation.

[14]  B. Mehta,et al.  Ferritin in Adult-Onset Still's Disease: Just a Useful Innocent Bystander? , 2012, International journal of inflammation.

[15]  J. Nolla,et al.  Adult onset Still's disease: review of 41 cases. , 2011, Clinical and experimental rheumatology.

[16]  H. Nossent,et al.  Epidemiology and outcome of adult‐onset Still's disease in Northern Norway , 2006, Scandinavian journal of rheumatology.

[17]  J. Piette,et al.  Proposal for a New Set of Classification Criteria for Adult-Onset Still Disease , 2002, Medicine.

[18]  A. Prost,et al.  Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. , 1995, Annals of the rheumatic diseases.

[19]  M. Akizuki,et al.  Preliminary criteria for classification of adult Still's disease. , 1992, The Journal of rheumatology.

[20]  M. Akizuki,et al.  Adult Still's disease: a multicenter survey of Japanese patients. , 1990, The Journal of rheumatology.

[21]  L. Cooperstein,et al.  Adult-onset Still's disease. Clinical course and outcome. , 1987, Arthritis and rheumatism.

[22]  I. Al-Homood,et al.  Biologic treatments for adult-onset Still's disease. , 2014, Rheumatology.

[23]  H. Boysson,et al.  Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence , 2012, Clinical Rheumatology.

[24]  A. Tamakoshi,et al.  Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. , 1997, Journal of epidemiology.